India Bans 344 Combination Drugs
The Ministry of Health and Family Welfare of
Government of India (GoI) has prohibited the manufacture, sale and
distribution of 344 fixed drug combinations (FDCs). Last year, the GoI
reviewed some 6200 combination drugs, of which nearly 15-20% were deemed
to be irrational or potentially harmful. The Expert Committee which
evaluated the drugs has made a list of the drugs which it felt had "no
therapeutic justification" and were likely to "involve risk to human
beings." According to US healthcare provider IMS Health, almost half the
drugs sold in India in 2014 were FDCs, making it a world leader in
combination drugs. A study published in the Journal of Public Library of
Science in May 2015 reported that 73% of non-steroidal anti-inflammatory
drug combinations were being marketed in India without central
government approval. In the banned list of 344 FDCs, 27 are
anti-diabetic drug combinations with metformin, 16 have the
anti-inflammatory drug nimesulide, 18 have diclofenac as one of the
ingredient, and half a dozen are codeine-containing cough syrups. The
list also includes commonly prescribed FDCs such as norfloxacin with
metronidazole, and cefixime with azithromycin. (The Times of India 12
March 2016)
Prediction of Tuberculosis
Researchers from the Centre for Infectious Disease
Research, Seattle, USA have evaluated a set of 16 genes which can be
used as biomarkers to predict the development of active tuberculosis
6-12 months before they develop symptoms. They followed up healthy,
South African adolescents (age 12–18 y) who were infected with M.
tuberculosis for 2 years, and collected blood samples every 6
months. When they compared the whole blood RNA sequencing of
participants who developed tuberculosis versus those who remained
healthy, they discovered a characteristic signature of risk. After
adaptation to multiplex quantitative real-time PCR (qRT-PCR), the
signature was used to predict tuberculosis disease in untouched
adolescent samples and in samples from independent cohorts of South
African and Gambian adult progressors and controls. The signature
predicted tuberculosis progression with a sensitivity of 66·1% (95% CI
63·2, 68·9) and a specificity of 80·6% (95% CI 79·2, 82·0) in the 12
months preceding tuberculosis diagnosis. (The Lancet 23 March 2016)
The Parliamentary Committee Report on the Medical
Council of India
A parliamentary committee has tabled a 126-page
report in the Rajya Sabha, which systematically dissects how and
why the council has failed in its mandate. It has made a long list of
the MCI’s failures, including failure to create a curriculum that
produces doctors suited to working in the Indian context, especially in
the rural health services and poor urban areas; failure to maintain
uniform standards of medical education; and devaluation of merit in
admission, particularly in private medical institutions due to the
prevalence of capitation fees. The report critiques the excessive focus
on the nitty-gritty of infrastructure and human staff during
inspections, but without a substantial evaluation of the quality of
teaching, training and imparting of skills. It also points out the
abysmal doctor–population ratio, and the failure to rationalize setting
up of medical colleges in the country as per needs, resulting in
geographical misdistribution with clustering in some states and the
absence in several others. In what is perhaps one of the most telling
statements, it describes what it terms the "failure to produce a
competent basic doctor." (Economic and Political Weekly 2 April 2016).
Yellow Fever Epidemic in Angola
There has been an unexpected yellow fever epidemic in Angola this
year. The outbreak, which was first reported in the capital city Luanda
in December 2015, has since spread to 5 of the country’s 18 provinces.
Yellow fever virus is transmitted by infected mosquitoes, the most
common species being Aedes aegypti – the same mosquito that
spreads the Zika virus. Symptoms include fever, headache, muscle pain,
nausea, vomiting and fatigue. A small percentage of infected people
experience a second more severe phase of illness which includes high
fever, jaundice and internal bleeding. At least half of severely
affected patients who do not receive treatment die within 10 to 14 days.
The WHO has begun an urgent vaccination campaign. (http://who.int/features/2016/angola-worst-yellow-fever/en/).